HIV Citation List: March 18, 2011- March 31, 2011

Pubmed citations

1. Analysis of Cyclotides in Viola ignobilis by Nano Liquid Chromatography Fourier Transform Mass Spectrometry. Hashempour, H., A. Ghassempour, N.L. Daly, B. Spengler, and A. Rompp. Protein & Peptide Letters, 2011. [Epub ahead of print]; PMID[21413917].

[Pubmed]. HIV_0318-033011.

2. Roles for Biological Membranes in Regulating Human Immunodeficiency Virus Replication and Progress in the Development of HIV Therapeutics that Target Lipid Metabolism. Haughey, N.J., Y.R.L.B. Tovar, and V.V. Bamdaru. Journal of Neuroimmune Pharmacology, 2011. [Epub ahead of print]; PMID[21445582].

[Pubmed]. HIV_0318-033011.

3. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Hoffmann, H.H., A. Kunz, V.A. Simon, P. Palese, and M.L. Shaw. Proceedings of the National Academies of Science, 2011. [Epub ahead of print]; PMID[21436031].

[Pubmed]. HIV_0318-033011.

4. Inhibition of HIV-1 and M-MLV reverse transcriptases by a major polyphenol (3,4,5 tri-O-galloylquinic acid) present in the leaves of the South African resurrection plant, Myrothamnus flabellifolia. Johns, B.A., HIV-1 Integrase Strand Transfer Inhibitors, in Annual Reports in Medicinal Chemistry, Vol 45. 2010. p. 263-+. 5. Kamng'ona, A., J.P. Moore, G. Lindsey, and W. Brandt. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[21443452].

[Pubmed]. HIV_0318-033011.

5. Antiviral Propierties of 5,5'-Dithiobis-2-Nitrobenzoic Acid and Bacitracin Against T-Tropic Human Immunodeficiency Virus Type 1. Lara, H.H., L. Ixtepan-Turrent, E.N. Garza-Trevino, S.M. Flores-Trevino, G. Borkow, and C. Rodriguez-Padilla. Virology Journal, 2011. 8(1): p. 137; PMID[21435237].

[Pubmed]. HIV_0318-033011.

6. Diarylpyrimidine-Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. Rotili, D., D. Tarantino, M. Artico, M.B. Nawrozkij, E. Gonzalez-Ortega, B. Clotet, A. Samuele, J.A. Este, G. Maga, and A. Mai. Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[21438533].

[Pubmed]. HIV_0318-033011.

7. Caveolin 1 inhibits HIV replication by transcriptional repression mediated through NF-{kappa}B. Wang, X.M., P.E. Nadeau, S. Lin, J.R. Abbott, and A. Mergia. Journal of Virology, 2011. [Epub ahead of print]; PMID[21430048].

[Pubmed]. HIV_0318-033011.

8. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Harris, K.S., W. Brabant, S. Styrchak, A. Gall, and R. Daifuku. Antiviral Research, 2005. 67(1): p. 1-9; PMID[15890415].

[Pubmed]. HIV_0318-033011.

9. Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside KP1461. Mullins, J.I., L. Heath, J.P. Hughes, J. Kicha, S. Styrchak, K.G. Wong, U. Rao, A. Hansen, K.S. Harris, and J.P. Laurent. PLoS ONE, 2011. 6(1): p. 483-489; PMID[21264288].

[Pubmed]. HIV_0318-033011.

ISI Web of Knowledge citations

10. Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine. Clouser, C.L., C.M. Holtz, M. Mullett, D.L. Crankshaw, J.E. Briggs, J. Chauhan, I.M. VanHoutan, S.E. Patterson, and L.M. Mansky. PLoS ONE, 2011. 6(1); ISI[000286516500013].

[WOS]. HIV_0318-033011.

11. The Antiviral Spectra of TRIM5 alpha Orthologues and Human TRIM Family Proteins against Lentiviral Production. Ohmine, S., R. Sakuma, T. Sakuma, T. Thatava, H. Takeuchi, and Y. Ikeda. PLoS ONE, 2011. 6(1); ISI[000286516500030].

[WOS]. HIV_0318-033011.

12. HIV Protease-Mediated Activation of Sterically Capped Proteasome Inhibitors and Substrates. Buckley, D.L., T.W. Corson, N. Aberle, and C.M. Crews. Journal of the American Chemical Society, 2011. 133(4): p. 698-700; ISI[000287295300017].

[WOS]. HIV_0318-033011.

13. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors. Majerz-Maniecka, K., R. Musiol, A. Skorska-Stania, D. Tabak, P. Mazur, B.J. Oleksyn, and J. Polanski. Bioorganic & Medicinal Chemistry, 2011. 19(5): p. 1606-1612; ISI[000287740200004].

[WOS]. HIV_0318-033011.

14. Cycloartane Triterpenes from the Apical Buds of Gardenia obtusifolia. Nuanyai, T., R. Sappapan, T. Vilaivan, and K. Pudhom, Gardenoins E-H. Chemical & Pharmaceutical Bulletin, 2011. 59(3): p. 385-387; ISI[000287792900016].

[WOS]. HIV_0318-033011.

15. Synthesis and biological evaluation of novel n- 3-(4-phenylpip-erazin-1-yl)-propyl -carboxamide derivatives. Yin, H.J., Y.X. Li, Y.T. Zheng, X.Y. Ye, C.Y. Li, Z.H. Zou, and Y. Zhao. Anti-HIV-1 activities of photodynamic therapy using hematoporphyrin monomethyl ether . 16. Weng, Z.Y., Y.P. Gao, J.K. Zhang, X.W. Dong, and T. Liu. Journal of Chemical Research, 2011(1): p. 43-46; ISI[000287848200013].

[WOS]. HIV_0318-033011.

16. Therapeutic Targets for Inhibitors of Glycosylation. Alonzi, D.S. and T.D. Butters. Chimia, 2011. 65(1-2): p. 35-39; ISI[000287981400007].

[WOS]. HIV_0318-033011.

17. Dithiothreitol Causes HIV-1 Integrase Dimer Dissociation While Agents Interacting With the Integrase Dimer Interface Promote Dimer Formation. Tsiang, M., G.S. Jones, M. Hung, D. Samuel, N. Novikov, S. Mukund, K.M. Brendza, A. Niedziela-Majka, D.B. Jin, X.H. Liu, M. Mitchell, R. Sakowicz, and R. Geleziunas. Biochemistry, 2011. 50(10): p. 1567-1581; ISI[000287997000001].

[WOS]. HIV_0318-033011.

18. From Conventional to Unusual Enzyme Inhibitor Scaffolds: The Quest for Target Specificity. Meggers, E. Angewandte Chemie-International Edition, 2011. 50(11): p. 2442-2448; ISI[000288037600005].

[WOS]. HIV_0318-033011.

19. Chemical Constituents of Plants from the Genus Geum. Serbin, A., E. Karaseva, V. Tsvetkov, O. Alikhanova, and I. Rodionov. Hybrid Polymeric Systems for Nano-Selective Counter Intervention in Virus Life Cycle . 21. Cheng, X.R., H.Z. Jin, J.J. Qin, J.J. Fu, and W.D. Zhang. Chemistry & Biodiversity, 2011. 8(2): p. 203-222; ISI[000288093200001].

[WOS]. HIV_0318-033011.

20. Henrischinins A-C: Three New Triterpenoids from Schisandra henryi. Xue, Y.B., J.H. Yang, X.N. Li, X. Du, J.X. Pu, W.L. Xiao, J. Su, W. Zhao, Y. Li, and H.D. Sun. Organic Letters, 2011. 13(6): p. 1564-1567; ISI[000288148800077].

[WOS]. HIV_0318-033011.

21. Synthetic Methods and Biological Activities of Clitocine and Its Analogues. Guo, X.H., H. Kang, L.X. Zheng, and S.D. Jiang. Chinese Journal of Organic Chemistry, 2011. 31(2): p. 176-186; ISI[000288184700003].

[WOS]. HIV_0318-033011.

22. Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors. Maddali, K., V. Kumar, C. Marchand, Y. Pommier, and S.V. Malhotra. Medchemcomm, 2011. 2(2): p. 143-150; ISI[000288297100008].

[WOS]. HIV_0318-033011.

23. Synthesis and Properties of 3 '-Azido-3 '-Deoxythymidine Derivatives of Glycerolipids. Lonshakov, D.V., E.O. Baranova, A.I. Lyutik, N.S. Shastina, and V.I. Shvets. Pharmaceutical Chemistry Journal, 2011. 44(10): p. 557-563; ISI[000288437700009].

[WOS]. HIV_0318-033011.

24. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Yoshinaga, T., M. Kanamori-Koyama, T. Seki, A. Sato, and T. Fujiwara. Antiviral Therapy, 2010. 15(S2): p.A141; ISI[000287431300116].

[WOS]. HIV_0318-033011.

25. Differential resistance in HIV-1 protease: the role of residue 50 in pathways for amprenavir/darunavir and atazanavir resistance. Bandaranayake, R.M., S. Mittal, N.M. King, M. Prabu-Jeyabalan, M.N.L. Nalam, and C.A. Schiffer. Antiviral Therapy, 2010. 15(S2): p.A14; ISI[000287431300010].

[WOS]. HIV_0318-033011.

26. Substrate envelope based design of potent HIV-1 protease inhibitors resilient to resistance. Nalam, M.N.L., A. Ali, G. Reddy, S.G. Anjum, T.M. Rana, and C.A. Schiffer. Antiviral Therapy, 2010. 15(S2): pA15; ISI[000287431300011].

[WOS]. HIV_0318-033011.

27. Resistance induction to the HIV-1 CD4 binding site inhibitor M48-U1. Grupping, K., L. Heyndrickx, K. Arien, G. Martin, L. Martin, and G. Vanham. Antiviral Therapy, 2010. 15(S2): p.A55; ISI[000287431300048].

[WOS]. HIV_0318-033011.

28. New insights into the mechanism of action of a new HIV-1 maturation inhibitor extracted from Brazilian brown algae Dictyota pfaffii. Abreu, C.M., A.L. Valadao, R. Delvechio, L.J. da Costa, D.C. Bou-Habib, C.C. Cirne-Santos, V.L. Teixeira, I. Frugulhetti, W. Ferreira, A. Tanuri, and R.M. Brindeiro. Antiviral Therapy, 2010. 15(S2): p.A57; ISI[000287431300050].

[WOS]. HIV_0318-033011.

29. Antiviral activity profile and characterization of mutations associated with resistance to a novel NRTI (OBP-601, Festinavir (R)) and their effect on HIV-1 replicative fitness. Vazquez, A.C., J. Weber, M. Baba, D. Winner, J.D. Rose, A.M. Rhea, D. Wylie, Y. Urata, and M.E. Quinones-Mateu. Antiviral Therapy, 2010. 15(S2): p.A66; ISI[000287431300059].

[WOS]. HIV_0318-033011.

30. Full-length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays. Gupta, R.K., A. Kohli, A. McCormick, G. Towers, D. Pillay, and C.M. Parry. Antiviral Therapy, 2010. 15(S2): pA69; ISI[000287431300073].

[WOS]. HIV_0318-033011.

31. The amino acid substitution A376S in the HIV-1 reverse transcriptase connection subdomain confers low-level phenotypic resistance to nevirapine. Puertas, M.C., M. Kisic, A. Cozzi-Lepri, W. Bannister, R. Bellido, C. Pou, B. Clotet, R. Paredes, J. Lundgren, L. Menendez-Arias, J. Martinez-Picado, and S.S.G. Euro. Antiviral Therapy, 2010. 15(S2): p.A70; ISI[000287431300074].

[WOS]. HIV_0318-033011.

32. In vitro HIV-1 cross-resistance against reverse transcriptase inhibitor-based microbicides. Selhorst, P., A.C. Vazquez, K. Terrazas-Aranda, J. Michiels, L. Heyndrickx, K. Arien, M.E. Quinones-Mateu, and G. Vanham. Antiviral Therapy, 2010. 15(S2): p.A112; ISI[000287431300116].

[WOS]. HIV_0318-033011.

Patent citations

33. Preparation of cyclodepsipeptide antiviral compounds for use in the treatment of HIV infections, AIDS and ARC. Alcami Pertejo, J., L.M. Bedoya del Olmo, and M.d.C. Cuevas Marchante. Patent. 2011. 2010-EP62174

2011020913.

[Patent]. HIV_0318-033111.

34. Methods and compositions of triazolyl oligosaccharides related to viral inhibition. Arya, D.P., N. Ranjan, and S. Kumar. Patent. 2011. 2010-857425 20110046982.

[Patent]. HIV_0318-033111.

35. A novel standardized plant composition comprising procyanidins for treatment of RNA virus infection including AIDS. Bhaskaran, S. and M. Vishwaraman. Patent. 2011. 2009-IN519 2011018793.

[Patent]. HIV_0318-033111.

36. Pyrimidine derivatives as novel viral replication inhibitors and their preparation and use in the treatment of HIV infection. Chaltin, P., Z. Debyser, M. De Maeyer, A. Marchand, D. Marchand, W. Smets, A. Voet, and F. Christ. Patent. 2011. 2010-EP61453 2011015641.

[Patent]. HIV_0318-033111.

37. Preparation of peptidyl macrocycles and their compositions for preventing or treating HIV infection. Gilon, C., A. Hoffman, M. Kotler, M. Hurevich, S. Joubran, and A. Swed. Patent. 2011. 2010-IL708 2011024175.

[Patent]. HIV_0318-033111.

38. Substituted (thiazolylcarbonyl)imidazolidinones as antiretroviral agents and their preparation and use in the treatment of retroviral diseases. Thede, K., S. Greschat, K.M. Gericke, S. Wildum, and D. Paulsen. Patent. 2011. 2010-EP61923 2011020822.

[Patent]. HIV_0318-033111.

39. HIV integrase inhibitors. Wai, J.S., D.-S. Su, and C.M. Wiscount. Patent. 2011. 2010-US45589 2011025683.

[Patent]. HIV_0318-033111.